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Chemokine Receptor ACKR2
Kave Shams1, Gillian J. Wilson1, Mark Singh1, Ellen H. van den Bogaard2, Michelle L. Le Brocq1,
Susan Holmes3, Joost Schalkwijk2, A. David Burden1,4, Clive S. McKimmie1,5,6 and Gerard J. Graham1,6Elucidating the poorly defined mechanisms by which inflammatory lesions are spatially restricted in vivo is of
critical importance in understanding skin disease. Chemokines are the principal regulators of leukocyte
migration and are essential in the initiation and maintenance of inflammation. The membrane-bound psoriasis-
associated atypical chemokine receptor 2 (ACKR2) binds, internalizes and degrades most proinflammatory
CC-chemokines. Here we investigate the role of ACKR2 in limiting the spread of cutaneous psoriasiform
inflammation to sites that are remote from the primary lesion. Circulating factors capable of regulating ACKR2
function at remote sites were identified and examined using a combination of clinical samples, relevant primary
human cell cultures, in vitro migration assays, and the imiquimod-induced model of psoriasiform skin
inflammation. Localized inflammation and IFN-g together up-regulate ACKR2 in remote tissues, protecting
them from the spread of inflammation. ACKR2 controls inflammatory T-cell chemotaxis and positioning within
the skin, preventing an epidermal influx that is associated with lesion development. Our results have important
implications for our understanding of how spatial restriction is imposed on the spread of inflammatory lesions
and highlight systemic ACKR2 induction as a therapeutic strategy in the treatment and prevention of psoriasis
and potentially a broad range of other immune-mediated diseases.
Journal of Investigative Dermatology (2017) 137, 85e94; doi:10.1016/j.jid.2016.07.039INTRODUCTION
Chemokines, the primary in vivo regulators of leukocyte
migration, are central to inflammatory pathogenesis (Rot and
von Andrian, 2004; Zlotnik and Yoshie, 2000). They bind to
7-transmembrane spanning receptors to orchestrate the
recruitment of inflammatory cells into and within tissues. In
addition to the classical signaling chemokine receptors
(Bachelerie et al., 2014a), there exists a subfamily of stro-
mally expressed atypical chemokine receptors that display
promiscuous ligand binding and atypical signaling responses
after ligand binding (Bachelerie et al., 2014b; Graham et al.,
2012; Nibbs and Graham, 2013). These atypical chemokine
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these molecules, atypical chemokine receptor 2 (ACKR2;
previously known as D6), is a high-affinity receptor for
multiple inflammatory CC-chemokines (Graham and Locati,
2013). ACKR2 does not mount classical signaling responses
after ligand binding (Borroni et al., 2013) but internalizes
ligands and targets them for intracellular degradation (Weber
et al., 2004). ACKR2 has therefore been characterized as a
scavenging receptor for inflammatory CC-chemokines.
ACKR2’s role in limiting the development of inflammation
is shown by numerous studies of ACKR2-deficient mice and
by reports of aberrant expression patterns in human inflam-
matory pathologies (Bazzan et al., 2012; Cochain et al.,
2012; Codullo et al., 2011; Singh et al., 2012).
Recently, we showed that ACKR2 expression is particularly
elevated in uninvolved skin of psoriatic patients (Singh et al.,
2012). We hypothesized that inflammatory products from
primary inflamed lesions limit the spread of chemokine-
dependent inflammation by driving systemic up-regulation
of ACKR2 at remote sites. Here, we present experimental
in vitro and in vivo validation of, and a mechanistic expla-
nation for, our hypothesis. We highlight circulating products
of the primary inflamed site, notably T-helper (Th) 1/Th17
cytokines, as inducers of remote ACKR2 expression. We
show an anti-inflammatory role for increased ACKR2
expression at remote noninflamed sites in vivo and provide a
mechanism whereby focal inflammation reduces the pro-
pensity for inflammation to spread to remote tissues through
modulation of ACKR2. Overall, we propose that dynamic
regulation of ACKR2 expression is an endogenous means for
limiting spread of psoriasiform inflammation.estigative Dermatology. This is an open access
www.jidonline.org 85
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Figure 1. ACKR2-deficient mice
display an exaggerated psoriasiform
phenotype in response to IMQ
treatment. (a) WT mice treated for 3
days (culled day 4) with (top) vehicle
control and (middle) IMQ; (bottom)
IMQ-treated ACKR2-deficient mice.
Scale bars ¼ 1 cm. (b) Hematoxylin
and eosin-stained WT and ACKR2-
deficient (KO) skin after 3 days of IMQ
treatment and quantification of
epidermal thickness after 3 or 6 days
of daily IMQ. Scale bars ¼ 100 mm.
Statistics: one-way analysis of
variance. (c) Ki67-stained WT and
ACKR2-deficient (KO) skin after 3 days
of IMQ and quantification of thickness
of Ki67 staining in the epidermis. (d)
(top) PASI skin inflammation and
(bottom) weight change (baseline ¼
100%) throughout treatments.
Statistics: two-way analysis of
variance, Tukey’s multiple
comparisons test. (e) Correlation
between mean epidermal thickness
and PASI score (left). Correlation
between mean thickness of
Ki67 positive epidermis and PASI
score (right). *P < 0.05, **P < 0.01.
ACKR2, atypical chemokine receptor
2; IMQ, imiquimod; KO, knockout;
NS, not significant; PASI, Psoriasis
Area Severity Index; WT, wild type.
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86RESULTS
ACKR2-deficient mice display exaggerated inflammation in
response to imiquimod
To establish a mouse model appropriate for assessing the
mechanism of differential ACKR2 regulation and the role of
ACKR2 in regulating localized inflammation, we determined
the role of ACKR2 in the well-characterized imiquimod (IMQ)
mouse model of psoriasis (van der Fits et al., 2009). At rest,
there are no histological differences in wild-type (WT) and
ACKR2-deficent skin (Baldwin et al., 2013; Jamieson et al.,
2005; Nibbs et al., 2007). However, in response to daily
topical IMQ application (Aldara cream, MedaJournal of Investigative Dermatology (2017), Volume 137Pharmaceuticals, Bishops Stortford, UK) and compared with
WT mice, ACKR2-deficient mice displayed an exaggerated
cutaneous inflammatory response (Figure 1a). This was asso-
ciated with significantly increased epidermal thickness
(Figure 1b, and see Supplementary Figure S1a online) and
keratinocyte proliferation (Figure 1c, and see Supplementary
Figure S1b). The dynamics of psoriasis-like pathology during
induction of inflammation was quantified using a modified
Psoriasis Area Severity Index (PASI) (see Supplementary
Figure S2a online), which showed that ACKR2-deficient
mice rapidly develop substantially worse pathology than WT
mice (Figure 1d). This was accompanied by significantly more
ab
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Figure 2. ACKR2 regulates T-cell
migration and positioning in the skin.
(a) CD3þ staining after 3 days of
treatment with IMQ. Arrows: CD3þ T
cells. Red line: dermal-epidermal
junction. (b) Distance of CD3þ cells
from basement membrane after 3 days
of treatment with IMQ. Two-way
analysis of variance, Sidak’s multiple
comparisons test. (c) Epidermal CD3þ
as percentage total CD3þ cells (one-
way analysis of variance, Tukey’s
multiple comparisons test). (d) T-cell
migration toward CCL5 (top of plots)
across low or high ACKR2-expressing
keratinocytes. Plots on left: cumulative
migration direction. Plots on right:
individual tracks (black ¼ toward and
red ¼ away from CCL5). Statistics:
Rayleigh test. (e) ACKR2 expression in
heart and liver from vehicle- (black
bars) or IMQ- (grey bars) treated mice.
(f) ACKR2 expression in draining
lymph nodes from treated or untreated
skin. Mice were treated 3 days with
vehicle (black bars) or IMQ (grey
bars). (g) ACKR2 at site of vehicle/IMQ
treatment and distal dorsal skin. **P <
0.01, ***P < 0.005, ****P < 0.0001.
ACKR2, atypical chemokine receptor
2; IMQ, imiquimod; KO, knockout;
NS, not significant; WT, wild type.
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Psoriasiform Inflammation is Restricted by ACKR2weight loss in ACKR2-deficient mice (Figure 1d). The PASI
score correlated directlywith the extent of epidermal thickness
and keratinocyte proliferation, which were both significantly
enhanced inACKR2-deficientmice (Figure 1e). Together, these
data show that ACKR2 is required for limiting inflammation in
a relevant in vivo model of psoriasis.
ACKR2 regulates chemokine-mediated T-cell migration to
control the positioning of CD3D T lymphocytes in vivo
T-cell migration into the epidermis is essential for the
development of psoriasiform inflammation (Conrad et al.,2007). We therefore determined the effect of ACKR2 on
CD3þ T-cell localization in the IMQ model. There are no
basal differences in total cutaneous or epidermal T-cell
numbers in ACKR2-deficient, compared with WT, mice
(Baldwin et al., 2013; Jamieson et al., 2005). However, there
was an increase in CD3þ T-cell numbers in skin of IMQ-
inflamed WT and ACKR2-deficient mice compared with
vehicle-treated mice (Figure 2a). Also, although T cells were,
in the main, excluded from inflamed WT epidermis
(Figure 2aec), they were able to migrate efficiently into
inflamed ACKR2-deficient epidermis, even in areas ofwww.jidonline.org 87
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Figure 3. Cytokines from activated T
cells induce ACKR2 expression in
human keratinocytes. ACKR2
expression in response to cytokines
(100ng/ml) in (a) human
keratinocytes, (b) skin equivalents
treated with activated CD4þ T cells
and (c) skin equivalents after 2e4 days
with/without treatment with all-trans
retinoic acid or cyclosporine A.
ACKR2 expression in (d) human
keratinocytes treated with T-cell
conditioned medium alone and (e)
human keratinocytes treated with anti
eIFN-g antibodies. Two-way analysis
of variance, Tukey’s MCT. (f) Mouse
IFN-g expression 24 hours after
treatment. Virus-infected samples act
as positive control. One-way analysis
of variance, Tukey’s multiple
comparisons test. (g) ACKR2
expression in mouse dorsal skin after
IFN-g treatment (20,000U/day for 4
days, n ¼ 6). Student t test. (h) WT
mice were treated for 3 days and
photographed on day 4. Scale bars ¼
1 cm. (i) PASI score. Arrows: first day
of IFN-g/phosphate buffered saline
injections and IMQ/vehicle. (j)
Correlation of cutaneous ACKR2
expression and PASI score. *P < 0.05,
**P < 0.01, ***P < 0.005, ****P <
0.0001. ACKR2, atypical chemokine
receptor 2; CsA, cyclosporine A; d,
days; IMQ, imiquimod; M, million;
NS, not significant; PASI, Psoriasis
Area Severity Index; RA, retinoic acid;
TBP, TATA-binding protein; Th, t
helper.
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88epidermis overlying dermis that exhibited relatively few T
cells (Figure 2a and see Supplementary Figure S3 online).
Next, to understand the mechanism by which ACKR2
controls T-cell localization in vivo, we tested whether ACKR2
expressed by a barrier layer of keratinocytes (as seen in the
skin dermal-epidermal junction) could regulate human T-cell
migration. For this purpose, we established an in vitro three-
dimensional cell migration assay. The T-cell chemoattractant
chemokine CCL20 has been associated with psoriasis (Lowes
et al., 2014). However, CCL20 does not bind to ACKR2
(Madigan et al., 2010) and thus will not contribute to the
altered T-cell localization. We therefore developed an assayJournal of Investigative Dermatology (2017), Volume 137using the ACKR2 ligand CCL5, which is highly expressed in
human psoriatic plaques (Singh et al., 2012) and is a potent
attractant for human T cells (Makino et al., 2002). CCL5 was
placed at the top of a skin collagen matrix, below which we
placed a barrier layer of primary human keratinocytes that
separated the chemokine from the T cells at the bottom of the
collagen-filled chamber (see Supplementary Figure S4
online). Cultured keratinocytes express low ACKR2 at rest
but can be induced to express very high levels (see Figure 3a
and c). Although a barrier of low-ACKR2-expressing kerati-
nocytes had little influence on T-cell migration toward CCL5,
high-ACKR2-expressing IFN-gestimulated keratinocytes
K Shams et al.
Psoriasiform Inflammation is Restricted by ACKR2effectively blocked directional migration of T cells toward the
chemokine (Figure 2d). This indicates that the up-regulation
of ACKR2 in the barrier layer of basal keratinocytes pre-
vents CCL5-induced directional T-cell migration into the
epidermis.
We next wanted to determine whether ACKR2 expression
is differentially modulated in the in vivo IMQ model of
psoriasis. We found that localized cutaneous inflammation
was associated with significantly increased ACKR2 transcript
expression in apparently uninvolved tissues located away
from the primary site of inflammation, including heart and
liver (Figures 2e). We noted no gross histological abnormal-
ities in these tissues in either WT or ACKR2e/e mice treated
with or without IMQ (see Supplementary Figure S5 online).
We refer to such sites (especially cutaneous sites) as being
remote from the primary inflammatory lesion. In contrast, no
differences were seen in ACKR2 transcript expression in
lymph nodes draining either inflamed or noninflamed cuta-
neous sites (Figure 2f). In keeping with our data from human
psoriasis (Singh et al., 2012), ACKR2 expression was reduced
within psoriasis-like inflammatory lesions of IMQ-treated
skin compared with noninflamed skin (Figure 2g). However,
and in contrast to the data for heart and liver, no significant
differences in cutaneous ACKR2 mRNA expression were seen
in skin remote from the site of IMQ treatment (Figure 2g).
Together, our data show that ACKR2 determines localiza-
tion of inflammatory T cells at sites of inflammation and that
localized inflammation, induced by IMQ, leads to remote up-
regulation of ACKR2 expression in noninflamed tissues.
Th1/Th17 cytokines induce ACKR2 expression in epidermal
keratinocytes and protect cutaneous sites from inflammation
Increased epidermal ACKR2 expression in human uninvolved
psoriatic skin and psoriatic peripheral blood leukocytes
(Singh et al., 2012) suggests regulation of expression by sys-
temic circulating factors derived from inflammatory plaques.
To gain insights into these factors in vivo we performed
multiplex analysis on plasma from healthy control subjects
and psoriatic patients. The most striking and significant dif-
ferences in psoriatic patients were seen with levels of cyto-
kines strongly associated with activated Th1 and Th17
phenotypes (see Supplementary Figure S6 online). We
therefore tested whether Th1/Th17 cytokines could increase
ACKR2 mRNA expression in healthy primary human kerati-
nocytes. Treatment of keratinocytes with cytokine cocktails,
representative of Th1 and Th17 cells, increased ACKR2
transcript expression (Figure 3a). In addition, and as previ-
ously reported (Singh et al., 2012), IFN-g was active as a
potent, single-agent inducer of ACKR2 mRNA expression.
We then examined how adding variable numbers of acti-
vated T-cells affected ACKR2 transcript expression in an
in vitro human skin equivalent model of psoriasis (van den
Bogaard et al., 2014). As shown (Figure 3b), activated T
cells dose-dependently increased ACKR2 expression in this
model, and the T-cell dependency of this effect was
confirmed using cyclosporine A (Figure 3c). Next, we
collected total conditioned medium from in vitro activated T
cells, which markedly increase keratinocyte ACKR2 mRNA
expression in a dose-dependent manner (Figure 3d). To assess
the relative contribution of IFN-g, tissue culture supernatantof activated human T cells was treated with antieIFN-g
antibodies, which neutralized the potent ACKR2-inducing
effect (Figure 3e). Because T-cell derived factors are major
regulators of keratinocyte ACKR2 expression, we additionally
assessed levels of these factors in the plasma of IMQ-treated
mice. Our analysis showed that IFN-g levels were below the
limits of detection of the assays. In addition, we did not
detect IFN-g expression within the inflammatory lesions in
IMQ-treated mice (Figure 3f). Thus, although the IMQ mouse
model recapitulates key aspects of the cutaneous pathology
of human psoriasis, it is not associated with elevated IFN-g
expression and does not recapitulate the high circulating
IFN-g levels observed in patients (see Supplementary
Figure S6). We therefore systemically injected IFN-g (as a
prototypic cytokine with ACKR2-inducing properties to better
model human disease) into mice, which led to a significant
increase in ACKR2 expression in dorsal skin (Figure 3g).
We next wanted to determine if increased ACKR2 could
protect mice from developing inflammation in response to
IMQ treatment. Because IFN-g is deficient in the IMQ model
of psoriasis, and thus incompletely recapitulates human dis-
ease, IFN-gwas injected into mice twice daily throughout the
IMQ treatment protocol, and the extent of inflammation was
determined. As shown (Figure 3h), IFN-g administration was
associated with reduced signs of inflammation in WT mice
after IMQ treatment and, using our modified PASI, this
reduction was shown to be significant (Figure 3i). In addition,
ELISA analyses showed no impact of IMQ or IFN-g on IFN-g
expression within the inflamed skin (in keeping with
Figure 3f) but showed up-regulation of the T-cell chemo-
attractant chemokines CCL5 and CCL20, which were
blocked in response to systemic IFN-g treatment (see
Supplementary Figure S7 online). CCL20 protein expression
was also induced in ACKR2-deficient mice after IMQ treat-
ment (see Supplementary Figure S7), and this was also
reduced by IFN-g treatment. In keeping with the reported
inhibitory effects of IFN-g on Th17 cell differentiation
(Harrington et al., 2005; Park et al., 2005), IL-17 levels were
reduced in IMQ-inflamed skin in response to IFN-g treatment
(see Supplementary Figure S7). ACKR2 transcript levels in
treated skin displayed a strong inverse correlation with the
PASI, supporting the conclusion that systemic (IFN-gedriven)
increases in ACKR2 expression ameliorated cutaneous in-
flammatory pathology (Figure 3j).
Remote cutaneous inflammation, together with IFN-g,
induces systemic up-regulation of ACKR2 and limits the
spread of inflammation
To determine the effect of localized inflammation on remote
cutaneous ACKR2 expression, we examined the impact of
local IMQ treatment of skin with concurrent systemic IFN-g
administration on remote skin ACKR2 expression. Systemic
administration of IFN-g led to significant increases in cuta-
neous ACKR2 expression at the local site of both control
cream and IMQ treatment (Figure 4a). Although IMQ treat-
ment alone did not result in increased ACKR2 transcript
levels at remote cutaneous sites (Figures 2g and 4a), IMQ
combined with systemic IFN-g significantly increased ACKR2
expression in remote skin to levels higher than those seen
with IFN-g alone (Figure 4a), thus successfully replicating thewww.jidonline.org 89
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Figure 4. Localized IMQ combined with systemic IFN-g ameliorates psoriasis-like pathology at both primary and distal sites in an ACKR2-dependent manner.
(a) ACKR2 expression (day 5) in treated and distal/remote untreated skin of IMQ-treated mice (days 1e4) in presence/absence of systemic IFN-g (20,000 U/day).
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Figure 5. Histological and
immunochemical analysis of primary
and secondary IMQ-treated skin sites.
(a, b) Representative images of
hematoxylin and eosin, Ki67, and
CD3þ staining and associated
quantification of (a) initial IMQ-
induced lesion with concurrent PBS or
systemic IFN-g (day 5) and (b) second
IMQ-induced lesion initiated after
cessation of initial IMQ/IFN-g or PBS
treatment (day 8) (as in Figure 4b). In
CD3þ images, dark red arrows ¼
epidermal CD3þ T cells and dark red
line ¼ dermal-epidermal junction. All
scale bars ¼ 100mm. (cef) Total CD3þ
T-cell numbers in IMQ-induced skin
lesion with concurrent PBS or
systemic IFN-g in (c, d) first lesion or
(e, f) second lesion after cessation of
systemic PBS or IFN-g treatment.
Numbers shown are for (c, e) whole
skin and (d, f) epidermis. Mean of
three separate fields of view/mouse. *P
< 0.05, **P < 0.01, ***P < 0.005,
****P < 0.0001. ACKR2, atypical
chemokine receptor 2; FOV, field of
view; H&E, hematoxylin and eosin;
IMQ, imiquimod; NS, not significant;
PASI, Psoriasis Area Severity Index;
PBS, phosphate buffered saline.
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Psoriasiform Inflammation is Restricted by ACKR2human psoriatic expression pattern of ACKR2. To examine
the sustained impact of IFN-g/IMQ up-regulation of remote
ACKR2 expression on subsequent cutaneous inflammatory
responses, we initially treated a primary skin site (right flank)
with IMQ with concurrent systemic administration of vehicle
control or IFN-g. The IMQ and IFN-g treatment was stopped
at day 4, and from that point onward a second remote non-
inflamed cutaneous site (left flank) was treated with topical
IMQ (experimental design summarized in Figure 4b). NoteStatistics: Student t test. (b) Experimental design. PASI score at (c) initial lesions an
site. Ear thickness was measured in mice treated on the flank with IMQ and system
lesions. First IMQ lesion was induced with concurrent PBS (grey bar) or IFN-g (bl
dermis. Epidermal/dermal separation confirmed by involucrin quantitative PCR (g
mice pretreated with systemic PBS or IFN-g (20,000 U/day) at (h) initial lesion and
< 0.01, ***P < 0.005, ****P < 0.0001. ACKR2, atypical chemokine receptor 2; IM
phosphate buffered saline.that mice receiving either vehicle or IFN-g in the absence of
IMQ treatment displayed no skin inflammation and had a
PASI score of 0. These essentially negative data are not
included in subsequent figures. As expected from the above
data, systemic IFN-g administration reduced pathology at the
primary treatment site (Figure 4c), which plateaued at day 5
in the vehicle-treated mice but at day 8 in the IFN-getreated
mice. Although we have no clear explanation for the
increased PASI score in the IFN-getreated mice betweend (d) lesion induced by IMQ at second site. (e) As in c and d with ear as second
ic IFN-g (20,000 U/day) or PBS. (f) ACKR2 expression in second IMQ-induced
ack bar). Statistics: Student t test. (g) ACKR2 expression in distal epidermis and
rey bars). Statistics: Student t test. PASI score of IMQ-treated ACKR2-deficient
at (i) secondary lesion. Statistics: two-way analysis of variance. *P < 0.05, **P
Q, imiquimod; NS, not significant; PASI, Psoriasis Area Severity Index; PBS,
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Figure 6. Schematic model of the main findings of the study. ACKR2,
atypical chemokine receptor 2; Th, T helper.
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92days 5 and 8, these data may also indicate a role for IFN-g in
delaying the inflammatory process. After cessation of IFN-g/
IMQ at the primary site, subsequent IMQ-induced inflam-
mation at the remote site (contralateral flank skin) was
reduced in mice receiving both IMQ and IFN-g for the initial
4 days (Figure 4d). We obtained similar data in which initial
systemic IFN-g in WT mice significantly reduced the in-
flammatory response to IMQ when using the ear as a distal
site of inflammation (Figure 4e). Q-PCR showed that local-
ized psoriasiform inflammation and IFN-g coordinately up-
regulated remote tissue ACKR2 transcript levels (Figure 4f)
and that this occurred predominantly in the epidermal layer
(Figure 4g). To confirm that the remote protective effect of
systemic IFN-g is mediated specifically by ACKR2, experi-
ments were also conducted in ACKR2-deficient mice. As
predicted, and in contrast to WT mice, IFN-g did not confer a
protective effect at either the initial (Figure 4h) or remote
(Figure 4i) IMQ treatment sites in ACKR2-deficient mice. In
fact, at some time points, IFN-g administration exacerbated
pathology, suggesting that in ACKR2-deficient mice with their
inherent inability to regulate inflammatory CC-chemokine
activity, IFN-geinduced chemokine expression can
contribute to pathology.
In agreement with the above data, we found that IFN-
gemediated ACKR2 up-regulation significantly protected
mice against IMQ-induced epidermal thickening, limited
epidermal hyperproliferation, and led to a relative exclusion
of T cells from the epidermis at the both the primary site and
secondary site of IMQ application (Figures 5a and b, and see
Supplementary Figure S8 online). When the ear was investi-
gated as a remote site in ACKR2e/e mice (as in Figure 4e),
IFN-g was seen to have no apparent effect, with the IMQ
treatment leading to increased dermal/epidermal thickening,
enhanced keratinocyte proliferation, and greater epidermal
T-cell recruitment compared with IMQ-treated WT ear skin
(see Supplementary Figure S9 online). More detailed analysis
of the phenotypes of the T cells infiltrating the whole skin (see
Supplementary Figure S10a online) and epidermis (seeJournal of Investigative Dermatology (2017), Volume 137Supplementary Figure 10b) indicated that there were no
differences in the overall numbers of each of the phenotypic
subsets identified entering the whole skin in response to IMQ
in the presence or absence of systemic IFN-g. In addition,
examining the T-cell populations specifically within the
epidermal compartment showed the anticipated increase in
CD3þ T-cell numbers in IMQ-treated ACKR2-deficient mice
and further showed that this was heavily skewed toward the
CD4þ T-cell subset. Differences in epidermal CD3þ cell
numbers in IFN-g and vehicle control-treated mice were not
simply reflective of differences in total cutaneous T-cell
numbers (Figures 5cef) but instead represented a specific
skin-wide positioning of T cells that excluded them from the
epidermal compartment. Thus, these data show that localized
psoriasiform inflammation, together with elevated circulating
IFN-g, as seen in human psoriasis, protects remote sites from
inflammation and that this occurs in an ACKR2-dependent
manner.
DISCUSSION
Mechanistic interactions between localized inflammatory
responses and remote tissues are poorly understood. Here we
provide evidence that one site of localized inflammation can
protect remote tissues from further inflammatory triggers
through induced up-regulation of the chemokine scavenging
receptor ACKR2. Our model of local and remote ACKR2
function is summarized in Figure 6.
As the main regulators of leukocyte migration, chemokine
function is highly regulated. This includes regulation by
ACKR2 through its ability to bind, internalize and degrade
proinflammatory CC-chemokines (Weber et al., 2004). In
psoriasis, ACKR2 is highly up-regulated in clinically unaf-
fected remote skin (Singh et al., 2012). Here, our data show
that remote up-regulation of ACKR2 occurs by soluble me-
diators released from inflammatory lesions and that this limits
the spread of inflammation to tissues remote to the original
lesion. Our results show that psoriasiform pathology is
exaggerated in the absence of ACKR2, with significantly
more CD3þ T cells localized to the epidermis. Previous work
has shown epidermal CD3þ T cells to be crucial for the
development of psoriatic lesions (Conrad et al., 2007) and
CCL5 to be implicated in their accumulation in the epidermis
(Collins et al., 2016; Fukuoka et al., 1998). ACKR2 may also
contribute to regulating the epidermal (and dermal) accu-
mulation of other inflammatory leukocytes attracted by CC-
chemokines, and thus, although our data focus on
epidermal T cells, they may have broader relevance for in-
flammatory cell involvement in pathogenesis. Thus, we pro-
vide a mechanism by which a pathology-induced decrease in
ACKR2 function can lead to uncontrolled T-cell (and possibly
other leukocyte) epidermal entry and, hence, exaggerated
inflammatory lesion development.
We found that IMQ-induced inflammation at one site,
when supplemented with psoriasis-associated IFN-g to more
closely mimic human disease, was able to modulate induc-
tion of new lesions at a second, remote site. Remote sites
exhibited increased ACKR2 expression that correlated with
restricted epidermal T-cell entry and skin thickening. The
ability of systemic IFN-g to increase ACKR2 expression, in
the context of a mouse pathology that does not otherwise
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both IFN-gedependent and eindependent inflammatory
diseases. In IFN-gedependent contexts, if systemic levels are
high enough, IFN-g from the inflamed site may regulate
ACKR2 in remote areas to limit the inflammatory spread. In
IFN-geindependent pathologies, systemic administration of
IFN-g can achieve the same end. Our data provide a mech-
anistic explanation for the previously described therapeutic
efficacy of systemic IFN-g administration in inflammatory
diseases including psoriasis (Cannon et al., 1989; Fierlbeck
and Rassner, 1990; Fierlbeck et al., 1990; Morhenn et al.,
1987; Stevens et al., 1998; Veys et al., 1997). However, the
use of IFN-g for the purpose of up-regulating ACKR2 in
humans is likely to be fraught with difficulties, not least
because of possible proinflammatory off-target effects and
likely injection site reactions (Johnson-Huang et al., 2012).
Accordingly, we propose that developing specific inducers of
ACKR2 chemokine scavenging provides a new therapeutic
approach to treat diseases such as psoriasis and possibly
other systemic inflammatory disorders. Remote sites were not
protected from developing lesions by IFN-g in the absence of
ACKR2, confirming that this observed protective effect is
dependent on ACKR2. This is, to our knowledge, is the first
demonstration that primary lesions can modulate the pro-
pensity of other sites to become inflamed and that this occurs
in an ACKR2-dependent manner.
Together our data suggest that remotely increasing ACKR2
expression levels limits development of cutaneous inflam-
matory responses and, therefore, highlight a potential thera-
peutic role in psoriasis and other inflammatory diseases for
agents capable of inducing ACKR2 expression.
MATERIALS AND METHODS
Mouse model of psoriasis
The IMQ mouse model was carried out as described (van der Fits
et al., 2009). All mouse experiments were performed under the
auspices of a UK Home Office license and with permission from the
University of Glasgow Ethics Committee. Six- to 8-week-old WT
(from Charles River Laboratories, Elphinstone, UK) and ACKR2-
deficient (Jamieson et al., 2005) mice on a C57BL/6J background
were used throughout the study. A minimum of six mice were used
per group in each of the experiments. IFN-getreated mice received
murine IFN-g (R&D Systems, Abingdon, UK) 10,000 or 20,000U
either intraperitoneally or subcutaneously twice daily (as indicated
in figures). IFN-g was reconstituted in 0.01% sterile BSA in phos-
phate buffered saline (Sigma-Aldrich, Dorset, UK). Mice were
assessed daily, and skin inflammation was scored using a modified
Psoriasis Area Severity Index (PASI) (see Supplementary Figure S2).
Ear thickness was measured using digital calipers on day of cull.
All tissues for RNA extraction were stored in RNAlater (Life
Technologies, Paisley, UK) for 24 hours at 4 C. For long-term stor-
age, RNAlater-treated tissues were stored at e80 C. Tissues for
histology and immunohistochemistry were fixed in 10% neutral
buffered formaldehyde (Sigma-Aldrich).
RNA extractions and quantitative PCR
RNAwas extracted and purified on RNeasy Micro columns with on-
column DNase digestion as per manufacturer’s instructions (Qiagen,
Manchester, UK). Quantitative PCR was performed as described in
the Supplementary Materials online.Sections and immunohistochemistry
For hematoxylin and eosin, Ki67, and CD3þ staining, paraffin-
embedded fixed skin was cut to 2-mm thickness. Heat-induced an-
tigen retrieval was performed in pH 6 sodium citrate buffer for 100
seconds at 125 C under pressure. Polyclonal rabbit anti-human
CD3 (1:100 dilution) and polyclonal rabbit anti-Ki67 (1:400) (both
Dako, Carpinteria, CA), or negative controls, were used and coun-
terstained with hematoxylin.
T-cell and keratinocyte growth and stimulation and
generation of human skin equivalents
Details are provided in the Supplementary Materials.
Migration assay
Details are provided in the Supplementary Materials.
Analysis of human plasma
Details are provided in the Supplementary Materials.
Dermal-epidermal splitting
Full-thickness mouse skin was submerged in 0.025-mmol/L EDTA
(LifeTechnologies, Paisley, UK) at 37 C, after which the epidermal
layer was curetted off, leaving the dermis intact. Both skin compo-
nents were immediately lysed in Qiazol, using a Qiagen TissueLyser
LT (Qiagen, Manchester, UK).
Statistics
Student t test, Mann-Whitney U tests, one-way analysis of variance,
two-way analysis of variance, and correlation tests were performed
in Prism Version 7.0 (GraphPad Software Inc., San Diego, CA), with
multiple comparisons tests as appropriate. Vector data were assessed
by the Rayleigh test for vector data in chemotaxis plugin in ImageJ
(available at http://imagej.nih.gov/ij/). P < 0.05 was deemed signif-
icant. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001. All data
are n  3 and given as mean  standard error of the mean unless
otherwise stated.
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